The Food and Drug Administration (FDA) has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea (OSA), a common sleep disorder. Zepbound, also known as tirzepatide, is specifically approved for patients with both obesity and moderate-to-severe OSA. This approval expands Zepbound’s indication beyond weight loss, which could improve insurance coverage opportunities for patients with this condition.
Source: https://www.statnews.com/2024/12/20/fda-approves-zepbound-sleep-apnea